Other

Commercial

Moderna Commercial decreased by 30.4% to $16.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 33.3%, from $24.00M to $16.00M. Over 3 years (FY 2022 to FY 2025), Commercial shows a downward trend with a -21.7% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2022
Last reportedQ1 2026May 1, 2026
Metric ID: other_accrued_commercial

Historical Data

12 periods
 Q4 '22Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$48.00M$137.00M$56.00M$40.00M$32.00M$36.00M$45.00M$24.00M$24.00M$21.00M$23.00M$16.00M
QoQ Change—+185.4%-59.1%-28.6%-20.0%+12.5%+25.0%-46.7%+0.0%-12.5%+9.5%-30.4%
YoY Change——+16.7%——-73.7%-19.6%-40.0%-25.0%-41.7%-48.9%-33.3%
Range$16.00M – $137.00M
CAGR-32.9%
Avg YoY Growth-33.2%
Median YoY Growth-36.7%

Frequently Asked Questions

What is Moderna's commercial?
Moderna (MRNA) reported commercial of $16.00M in Q1 2026.
How has Moderna's commercial changed year-over-year?
Moderna's commercial decreased by 33.3% year-over-year, from $24.00M to $16.00M.
What is the long-term trend for Moderna's commercial?
Over 3 years (2022 to 2025), Moderna's commercial has grown at a -21.7% compound annual growth rate (CAGR), from $48.00M to $23.00M.